The NCCN Clinical Practice Guidelines in Oncology™ for Chronic Myelogenous Leukemia have been updated.
The updates include the addition of PEG-interferon (PEG-IFN) as an alternative to IFN in specified circumstances. Also, for patients not responding to treatment with imatinib, an evaluation of drug-drug interactions was added to the assessment for patient compliance.
The FDA black box warning for nilotinib was added as an attachment to alert clinicians of important considerations with the use of nilotinib. In addition, some of the response categories were reclassified based upon treatment recommendations.